<DOC>
	<DOCNO>NCT00161785</DOCNO>
	<brief_summary>The purpose study ass : - TBE antibody persistence 2 3 year third TBE vaccination FSME-IMMUN 0.5ml mean ELISA neutralization test ( NT ) . - TBE antibody response booster vaccination FSME-IMMUN 0.5ml , mean ELISA NT .</brief_summary>
	<brief_title>Investigation Seropersistence TBE Antibodies Booster Response FSME-IMMUN 0.5 ml Adults Aged 18 - 67 Years</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Tick-Borne</mesh_term>
	<criteria>Male female subject eligible participation study : understand nature study , agree provision provide write informed consent ; receive third vaccination FSMEIMMUN 0.5ml course Baxter Study 213 ; blood drawn third vaccination course Baxter Study 213 ; show ELISAconcentration &gt; 126 VIE U/ml / NTtiter &gt; = 1:10 third vaccination Baxter Study 213 ; agree keep Subject Diary . Subjects exclude participation study : receive TBE vaccination since third vaccination FSMEIMMUN 0.5ml ; receive vaccination yellow fever / Japanese Bencephalitis since third vaccination FSMEIMMUN 0.5ml ; know HIV positive ( special HIV test require purpose study ) since third vaccination FSMEIMMUN 0.5ml ; know suspect problem drug alcohol abuse ( &gt; 4 liter wine / week equivalent level alcoholic beverage ) ; receive blood transfusion immunoglobulin within one month first second blood draw ; participate another Baxter vaccine study within last six month ( exception followup study ) . Subjects eligible booster vaccination : meet inclusion/exclusion criterion ; clinically healthy , ( i.e . physician would reservations vaccinate FSMEIMMUN 0.5ml outside scope clinical trial ) ; suffer disease ( e.g . autoimmune disease ) undergo form treatment ( e.g . systemic corticosteroid ) expect influence immunological function ; donate blood plasma within one month booster vaccination ; female childbearing potential pregnant breastfeeding booster vaccination ( positive pregnancy test result medical examination booster vaccination ) ; show allergic reaction one component vaccine since third vaccination Baxter Study 213 ; simultaneously participate another clinical trial include administration investigational product within six week prior booster vaccination end study . Subjects meet inclusion/exclusion criterion , febrile illness ( body temperature &gt; = 38.0Â°C , measure orally ) schedule time vaccination , vaccinate body temperature return normal . Subjects receive vaccination within two week prior booster vaccination vaccinate interval two week pass . If subject receive antipyretic within 4 hour prior intend TBE vaccination , vaccination perform late time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>